TNF inhibitor use during pregnancy linked to higher infant birthweight
Tumor necrosis factor inhibitor use by pregnant women with well-controlled rheumatoid arthritis is associated with a reduced risk for having a child that is born small for gestational age, study findings indicate.
Botulinum toxin A injection may ease base-of-thumb osteoarthritis pain
Intra-articular injection with botulinum toxin A results in clinically meaningful pain reduction for up to 3 months in people with base-of-thumb osteoarthritis, French study findings indicate.
Bimekizumab demonstrates sustained benefits in PsA, ankylosing spondylitis
Follow-up results from the BE ACTIVE and BE AGILE phase 2b trials show that the efficacy and safety profiles of bimekizumab are maintained for up to 3 years in patients with psoriatic arthritis or ankylosing spondylitis.
TNF inhibitors linked to higher psoriasis risk than other RA treatments
Treatment with tumor necrosis factor inhibitors (TNFi) is associated with a twofold increased risk for new-onset psoriasis compared with nonbiologic agents, suggest findings from a Danish cohort study.
VROOM trial: Pausing methotrexate doubles antibody response to COVID-19 booster vaccine
Holding methotrexate treatment for 2 weeks following administration of a booster dose of vaccines against SARS-CoV-2 significantly improves the humoral immune response to vaccination, suggest findings from a randomized controlled trial.
Maintenance therapy discontinuation may be risky in proliferative lupus nephritis
Individuals who discontinue maintenance immunosuppressive therapy for proliferative lupus nephritis after 2–3 years have a higher rate of relapse and severe flares than those who continue with treatment, suggest data from the WIN-Lupus trial.
TNF inhibitor tapered T2T strategy feasible in PsA and axSpA
A tapering treat-to-target strategy can lead to a large reduction in TNF inhibitor dose without impacting disease control in people with psoriatic arthritis or axial spondyloarthritis, study findings indicate.
